Literature DB >> 1737736

An examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder.

C S Gelernter1, M B Stein, M E Tancer, T W Uhde.   

Abstract

BACKGROUND: We investigated whether patients with DSM-III-R panic disorder and patients with social phobia could be distinguished on the basis of selected demographic variables and by several commonly used anxiety and phobia rating scales.
METHOD: Sixty-six patients with social phobia and 60 patients with panic disorder (42 with and 18 without agoraphobia) were studied. Subjects completed a battery of self-report measures that assessed phobic fears, avoidance, and related problems.
RESULTS: Social phobic patients showed an earlier age at onset than the panic disorder group, and there was a trend for more social phobics to have never married. Social phobics reported significantly greater levels of social phobic avoidance and distress, fear of negative evaluation, and avoidance of social situations than the panic disorder patients who reported more overall anxiety and rated themselves as significantly more avoidant of situations involving exposure to public places and to blood or injury. Discriminant function analyses showed that social phobic and panic disorder patients can be reliably discriminated on these scales.
CONCLUSION: The results of this study lend further support for the validity of the DSM-III-R nosologic distinctions between social phobia and panic disorder. Furthermore, generalized social phobia appears to be remarkably different from discrete social phobia on these measures. This study provides less support for considering panic disorder with agoraphobia to be distinct from panic disorder without agoraphobia.

Entities:  

Mesh:

Year:  1992        PMID: 1737736

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study.

Authors: 
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 3.  Social phobia. Epidemiology and cost of illness.

Authors:  J D Lipsitz; F R Schneier
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

4.  The Composite International Diagnostic Interview (CIDI-Auto): problems and remedies for diagnosing panic disorder and social phobia.

Authors:  Adrienne Means-Christensen; Cathy D Sherbourne; Peter Roy-Byrne; Michelle G Craske; Alexander Bystritsky; Murray B Stein
Journal:  Int J Methods Psychiatr Res       Date:  2003       Impact factor: 4.035

Review 5.  Issues in the assessment of social phobia: a review.

Authors:  Andrea M Letamendi; Denise A Chavira; Murray B Stein
Journal:  Isr J Psychiatry Relat Sci       Date:  2009       Impact factor: 0.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.